Therapeutic Classification: antineoplastics
Pharmacologic Classification: podophyllotoxin derivatives
High Alert
Absorption: Variably absorbed after oral administration (bioavailability ~50%). IV administration results in complete bioavailability.
Distribution: Rapidly distributed; poorly enters the CSF; probably crosses placenta; enters breast milk.
Protein Binding: 97%.
Half-Life: 411 hr.
(noted as effects on blood counts)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | unknown | 714 days (granulocytes) 916 days (platelets) | 20 days |
IV | unknown | 714 days (granulocytes) 916 days (platelets) | 20 days |
Contraindicated in:
Use Cautiously in:
CV: hypotension(IV)
Derm: alopecia, pruritis, rash, urticaria
Endo: sterility
GI: anorexia, diarrhea, nausea, vomiting, abdominal pain, stomatitis
Hemat: anemia, leukopenia, thrombocytopenia
Local: phlebitis at IV site
Neuro: drowsiness, fatigue, peripheral neuropathy
Drug-drug:
Testicular Neoplasms
Small-Cell Carcinoma of the Lung
Lab Test Considerations:
Fatalities have occurred with incorrect administration of chemotherapeutic agents. Before administering, clarify all ambiguous orders; double check single, daily, and course-of-therapy dose limits; have second practitioner independently double check original order, calculations and infusion pump settings. .
Do not confuse etoposide with etoposide phoshpate.
IV Administration: